Synthetic heparan sulfate oligosaccharides inhibit endothelial cell functions essential for angiogenesis

PLoS ONE

Volumn 5, Issue 7, 2010, Pages 1-15

  Cole, Claire L ^a   Hansen, Steen U ^a   Baráth, Marek ^b   Rushton, Graham ^a   Gardiner, John M ^a   Avizienyte, Egle ^a   Jayson, Gordon C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

F ACTIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; HEPARAN SULFATE; MITOGEN ACTIVATED PROTEIN KINASE; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR 2; CYTOKINE; LISSAMINE RHODAMINE B; OLIGOSACCHARIDE; RHODAMINE;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LAMELLIPODIUM; MOUSE; NONHUMAN; PROTEIN ASSEMBLY; PROTEIN CARBOHYDRATE INTERACTION; SIGNAL TRANSDUCTION; SULFATION; CELL CULTURE; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; FLUORESCENCE MICROSCOPY; IMMUNOBLOTTING; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; VASCULAR ENDOTHELIUM; WOUND HEALING;

CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; ENDOTHELIUM, VASCULAR; HEPARITIN SULFATE; HUMANS; IMMUNOBLOTTING; MICROSCOPY, FLUORESCENCE; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGOSACCHARIDES; RHODAMINES; STRUCTURE-ACTIVITY RELATIONSHIP; WOUND HEALING;

EID: 77955347373     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011644     Document Type: Article

References (32)

1. lagher JT (2006) Multiprotein signalling complexes: regional assembly on heparan sulphate. Biochem Soc Trans 34: 438-441.
2. Mulloy B, Rider CC (2006) Cytokines and proteoglycans: an introductory overview. Biochem Soc Trans 34: 409-413.
3. Stringer SE (2006) The role of heparan sulphate proteoglycans in angiogenesis. Biochem Soc Trans 34: 451-453.
4. Mohammadi M, Olsen SK, Ibrahimi OA (2005) Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 16: 107-137.
5. Pye DA, Vives RR, Turnbull JE, Hyde P, Gallagher JT (1998) Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem 273: 22936-22942.
6. Goodger SJ, Robinson CJ, Murphy KJ, Gasiunas N, Harmer NJ, et al. (2008) Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms. J Biol Chem 283: 13001-13008.
7. Pye DA, Vivès RR, Hyde P, Gallagher JT (2000) Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dependent on specific structural features: differential requirements for the modulation of FGF-1 and FGF-2. Glycobiology 10: 1183-1192.
8. Robinson CJ, Mulloy B, Gallagher JT, Stringer SE (2006) VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J Biol Chem 281: 1731-1740.
9. Abramsson A, Kurup S, Busse M, Yamada S, Lindblom P, et al. (2007) Defective N-sulfation of heparan sulfate proteoglycans limits PDGF-BB binding and pericyte recruitment in vascular development. Genes Dev 21: 316-331.
10. Lever R, Page CP (2002) Novel drug development opportunities for heparin. Nat Rev Drug Discov 1: 140-148.
11. Ludwig RJ, Alban S, Bistrian R, Boehncke WH, Kaufmann R, et al. (2006) The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on blood-borne metastasis in vivo. Thromb Haemost 95: 535-540.
12. Norrby K (2006) Low-molecular-weight heparins and angiogenesis. APMIS 114: 79-102.
13. Hasan J, Shnyder SD, Clamp AR, McGown AT, Bicknell R, et al. (2005) Heparin octasaccharides inhibit angiogenesis in vivo. Clin Cancer Res 11: 8172-8179.
14. Hansen SU, Jayson GC, Gardiner JM, Baráth M (2009) Process for the industrial production of L-iduronate containing polysaccharides. PCT Int Appl WO2009098449.
15. Hansen SU, Baráth M, Salameh BA, Pritchard RG, Stimpson WT, et al. (2009) Scalable synthesis of L-iduronic acid derivatives via stereocontrolled cyanohydrin reaction for synthesis of heparin-related disaccharides. Org Lett 11: 4528-4531.
16. Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8: 464-78.
17. Lamalice L, Le Boeuf F, Huot J (2009) Endothelial cell migration during angiogenesis. Circ Res 100: 782-794.
18. Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6: 56-68.
19. Lamalice L, Houle F, Jourdan G, Huot J (2004) Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 23: 434-445.
20. Takahashi T, Yamaguchi S, Chida K, Shibuya M (2001) A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 20: 2768-2778.
21. Noti C, de Paz JL, Polito L, Seeberger PH (2006) Preparation and use of microarrays containing synthetic heparin oligosaccharides for the rapid analysis of heparin-protein interactions. Chem Eur J 12: 8664-8686.
22. de Paz JL, Angulo J, Lassaletta JM, Nieto PM, Redondo-Horcajo M, et al. (2001) The activation of fibroblast growth factors by heparin: synthesis, structure, and biological activity of heparin-like oligosaccharides. Chembiochem 2: 673-685.
23. Baleux F, Loureiro-Morais L, Hersant Y, Clayette P, Arenzana-Seisdedos F, et al. (2009) A synthetic CD4-heparan sulfate glycoconjugate inhibits CCR5 and CXCR4 HIV-1 attachment and entry. Nat Chem Biol 5: 743-748.
24. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC (1996) Heparin structure and interactions with basic fibroblast growth factor. Science 271: 1116-1120.
25. Turnbull JE, Fernig DG, Ke Y, Wilkinson MC, Gallagher JT (1992) Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 267: 10337-10341.
26. Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, et al. (2001) Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J Biol Chem 276: 37900-37908.
27. Zhang F, Zhang Z, Lin X, Beenken A, Eliseenkova AV, et al. (2009) Compositional analysis of heprin/heparin sulphate interacting with fibroblast growth factor-fibroblast growth factor receptor complexes. Biochemistry 48: 8379-8386.
28. Boilly B, Vercoutter-Edouart AS, Hondermarck H, Nurcombe V, Le Bourhis X (2000) FGF signals for cell proliferation and migration through different pathways. Cytokine Growth Factor Rev 11: 295-302.
29. Huang C, Jacobson K, Schaller MD (2004) MAP kinases and cell migration. J Cell Sci 117: 4619-4628.
30. Bhattacharya R, Kwon J, Li X, Wang E, Patra S, et al. (2009) Distinct role of PLCb3 in VEGF-mediated directional migration and vascular sprouting. J Cell Sci 122: 1025-1034.
31. Soker S, Fidder G, Neufeld G, Klagsbrun M (1996) Characterization of novel vascular endothelial factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 271: 5761-5767.
32. Eliceiri BP, Puente XS, Hood JD, Stupack DG, Schlaepfer DD, Huang XZ, Sheppard D, Cheresh DA (2002) Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol 157: 149-160.